Preserving measured tissue after surgery could be useful, but it is not the same endpoint as returning home or walking independently. This small pilot primarily investigated biological and body-composition responses. Primary study
Design and reported findings
Twenty patients after hip-fracture surgery were randomized to growth hormone or placebo in a four-week double-blind study, followed by two additional months of observation. The authors reported increased IGF-1 and preservation of lean mass and bone mineral content without serious adverse events in this small sample. Imaging included DXA and quantitative CT. Primary report
Our appraisal: match the conclusion to the endpoint
Bone mineral content, bone density, and fracture healing are related but different concepts. A favorable mineral-content observation cannot be automatically translated into faster union, fewer subsequent fractures, or restored mobility.
Lean mass also does not directly measure strength or physical independence. After an injury, functional outcomes depend on many factors beyond tissue quantity, including pain, rehabilitation, cognition, and pre-existing limitations. A tissue-preservation result therefore needs direct functional follow-up.
The sample is too small to characterize uncommon harms reliably. No observed serious adverse event does not establish broad safety, especially for a heterogeneous postoperative population. The duration and completeness of monitoring remain important.
Follow-up after a short intervention can help assess persistence, but the timing of each reported endpoint must be checked. A summary should not imply that every favorable measurement remained unchanged throughout the entire observation period unless the data demonstrate that.
This pilot provides an exploratory signal rather than a recovery guarantee. It does not justify extrapolation to all fractures, different growth-hormone strategies, or critical illness. Full review should inspect baseline balance, hydration-related measurement issues, missing follow-up, functional endpoints, and adverse-event definitions. Clinical benefit must be assessed directly rather than inferred solely from the hormone and scan results.
Frequently asked questions
How many patients were randomized?
Was the trial placebo controlled and blinded?
Yes.
Were tissue-related outcomes favorable?
The authors reported preservation of lean mass and bone mineral content.
Does mineral content directly establish fracture healing?
No.
Does lean mass directly establish walking independence?
No.
Does no serious event in a small pilot prove broad safety?
No.
What additional evidence matters most for recovery claims?
Direct functional outcomes and adequately assessed harms.